Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

MRNA Moderna, Inc.

交易中 02-27 14:10:12 EST

51.59

-0.12

-0.23%

最高52.59	最低50.73	成交量368.95万
今开51.27	昨收51.71	日振幅3.60%
总市值203.75亿	流通市值187.42亿	总股本3.95亿
成交额1.91亿	换手率1.02%	流通股本3.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"MRNA","market":"US","secType":"STK","nameCN":"Moderna, Inc.","latestPrice":51.59,"timestamp":1772219409347,"preClose":51.71,"halted":0,"volume":3689488,"delay":0,"changeRate":-0.0023206343067104515,"floatShares":363290461,"shares":394939400,"eps":-7.26,"marketStatus":"交易中","change":-0.12,"latestTime":"02-27 14:10:12 EST","open":51.27,"high":52.59,"low":50.73,"amount":190576713.535824,"amplitude":0.03597,"askPrice":51.6,"askSize":40,"bidPrice":51.58,"bidSize":108,"shortable":3,"etf":0,"ttmEps":-7.26,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1544158800000,"exchange":"NASDAQ","adjPreClose":51.71,"preHourTrading":{"tag":"盘前","latestPrice":51.47,"preClose":51.71,"latestTime":"09:29 EST","volume":26340,"amount":1360214.1942,"timestamp":1772202590071,"change":-0.24,"changeRate":-0.004641,"amplitude":0.017405},"postHourTrading":{"tag":"盘后","latestPrice":51.49,"preClose":51.71,"latestTime":"19:58 EST","volume":52904,"amount":2733844.4252,"timestamp":1772153909261,"change":-0.22,"changeRate":-0.004254,"amplitude":0.015084},"volumeRatio":0.620633,"optionData":{"bulkOrders":[{"symbol":"MRNA","call":true,"expireDate":1772168400000,"strike":"47.5","timestamp":1772214053525,"price":4.28,"volume":4199,"amount":1797172,"type":"+"},{"symbol":"MRNA","call":true,"expireDate":1772168400000,"strike":"49.5","timestamp":1772214053525,"price":2.29,"volume":4199,"amount":961571,"type":"-"}]},"impliedVol":0.8,"impliedVolPercentile":0.6016},"requestUrl":"/m/hq/s/MRNA/wiki","defaultTab":"wiki","newsList":[{"id":"1120259381","title":"Moderna赢得欧盟对mRNA新冠-流感联合疫苗的支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1120259381","media":"老虎资讯综合","labels":["corporation","movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120259381?lang=zh_cn&edition=full","pubTime":"2026-02-27 19:54","pubTimestamp":1772193265,"startTime":"0","endTime":"0","summary":"联合疫苗是Moderna摆脱对单一新冠疫苗依赖、实现业务增长战略的重要组成部分。在一项后期临床试验中，Moderna将接种其联合疫苗的人群，与在同一次就诊中分别接种竞争对手流感疫苗及Moderna新冠疫苗的人群进行比较。结果显示，在50岁及以上成年人中，Moderna的联合疫苗针对两种病毒所产生的免疫反应均高于已获批的流感和新冠疫苗。","market":"us","thumbnail":"https://static.tigerbbs.com/0600218936ae0bee3ba761a283aa6f69","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0600218936ae0bee3ba761a283aa6f69"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moderna赢得欧盟对mRNA新冠-流感联合疫苗的支持","news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":0},{"id":"2613730353","title":"Piper Sandler上调莫德纳目标价至69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2613730353","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613730353?lang=zh_cn&edition=full","pubTime":"2026-02-23 14:40","pubTimestamp":1771828834,"startTime":"0","endTime":"0","summary":"格隆汇2月23日｜Piper Sandler将莫德纳目标价从63美元上调至69美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223144112a7151e48&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260223144112a7151e48&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4568","BK4533","MRNX","BK4551","BK4501","BK4585","MRNY","BK4588","BK4532","BK4534","MRNA","BK4139"],"gpt_icon":0},{"id":"2612287922","title":"BioNTech控告Moderna侵犯新冠疫苗专利","url":"https://stock-news.laohu8.com/highlight/detail?id=2612287922","media":"环球市场播报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612287922?lang=zh_cn&edition=full","pubTime":"2026-02-20 03:26","pubTimestamp":1771529160,"startTime":"0","endTime":"0","summary":"德国生物制药公司BioNTech周四在特拉华州联邦法院起诉Moderna，指控Moderna的新冠疫苗 mNEXSPIKE侵犯了BioNTech和辉瑞公司的竞争性疫苗Comirnaty的相关专利。　　该诉讼称，Moderna公司于2025年获得美国食品药品管理局批准的下一代新冠疫苗mNEXSPIKE，侵犯了BioNTech公司在用于简化mRNA疫苗设计的技术方面的权利，该技术允许以较低剂量为患者接种。　　Moderna在2022年起诉BioNTech及其合作伙伴辉瑞公司侵犯了Comirnaty的专利权，目前诉讼仍在进行中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnkyhw6558658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRNX","BNTX","MRNA","MRNY"],"gpt_icon":1},{"id":"1102127485","title":"异动解读 | FDA立场转变改善流感疫苗监管前景，Moderna盘中大涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102127485","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102127485?lang=zh_cn&edition=full","pubTime":"2026-02-20 02:59","pubTimestamp":1771527578,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘中股价大幅上涨5.06%，引起了市场的广泛关注。消息面上，美国食品和药物管理局改变了方针，将审查Moderna新型流感疫苗mRNA-1010的修订申请。此前一周，FDA曾拒绝了该疫苗的申请，引发了市场担忧，而此次立场的迅速反转显著改善了该疫苗的监管前景。多家券商随即更新了观点，其中William Blair将Moderna流感疫苗获得监管成功的概率从10%大幅提高到55%。RBC Capital Markets认为，FDA的迅速反转符合当前政策模式。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","MRNA","MRNY"],"gpt_icon":0},{"id":"2612405943","title":"莫德纳mRNA流感疫苗获FDA受理，计划2026年流感季使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2612405943","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612405943?lang=zh_cn&edition=full","pubTime":"2026-02-19 04:11","pubTimestamp":1771445460,"startTime":"0","endTime":"0","summary":"2026年2月19日消息，莫德纳采用mRNA技术的流感疫苗上市申请已获FDA受理，审批截止日期为2026年8月1日。此前FDA曾以临床试验设计存在缺陷为由拒绝受理，后改变立场同意审核。为加速获批，莫德纳提出分年龄段监管路径，为50至64岁人群寻求常规批准，为65岁及以上人群寻求加速批准，并承诺在老年人群中开展追加研究。若顺利获批，该疫苗计划于2026年晚些时候的流感季面向老年人群使用。以上内容基于公开资料整理，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219042437a4b13bd4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260219042437a4b13bd4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4568","BK4534","BK4139","BK4548","BK4532","BK4501","BK4551","BK4585","MRNA","BK4533"],"gpt_icon":0},{"id":"2612441990","title":"美股异动丨莫德纳(MRNA.US)涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612441990","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612441990?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:36","pubTimestamp":1771425360,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4568","BK4139","BK4532","SRTY","BK4585","MNQmain","BK4588","UWM","TZA","BK4535","BK4550","TNA","BK4551","IWN","MRNA","RWM","BK4548","TWM","BK4501","BK4533","BK4581","BK4534","IWO"],"gpt_icon":0},{"id":"2612405912","title":"莫德纳盘中异动 早盘股价大涨6.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612405912","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612405912?lang=zh_cn&edition=full","pubTime":"2026-02-18 22:31","pubTimestamp":1771425070,"startTime":"0","endTime":"0","summary":"北京时间2026年02月18日22时31分，莫德纳股票出现异动，股价大幅拉升6.01%。截至发稿，该股报46.57美元/股，成交量110.469万股，换手率0.28%，振幅1.47%。莫德纳股票所在的生物技术行业中，整体跌幅为0.48%。莫德纳公司简介：莫德纳是一家商业阶段的生物技术公司，成立于 2010 年，并于 2018 年 12 月首次公开募股。截至 2025 年 8 月，莫德纳有 35 种 mRNA 开发候选药物处于临床研究中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218223110a7077586&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218223110a7077586&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4501","BK4532","BK4568","BK4139","MRNA","BK4585","BK4534","BK4588","BK4548","BK4551","SNSE","BK4533"],"gpt_icon":1},{"id":"1131104661","title":"FDA同意审查Moderna季节性流感疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1131104661","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131104661?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:52","pubTimestamp":1771419126,"startTime":"0","endTime":"0","summary":"此前该公司宣布美国食品药品监督管理局已同意审查其在研季节性流感疫苗mRNA-1010的生物制品许可申请。FDA的这一决定是在A类会议后做出的,Moderna在会上提出了该候选疫苗的修订监管方案。Moderna的修订方案寻求对50至64岁成年人的完全批准,以及对65岁及以上人群的加速批准,并承诺在上市后要求中对老年人进行额外研究。Moderna预计mRNA-1010将在2026年获得首批潜在批准,具体取决于各个市场正在进行的监管审查。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8e8e39a7beb148acde163c9bfa12c7e1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA同意审查Moderna季节性流感疫苗","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNA"],"gpt_icon":1},{"id":"2612059454","title":"格隆汇2月18日 Moderna总裁表示希望秋季能将流感疫苗推向市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2612059454","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612059454?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:49","pubTimestamp":1771418940,"startTime":"0","endTime":"0","summary":"2月18日格隆汇消息，Moderna总裁称期望在秋季把流感疫苗推向市场。这一表态体现了Moderna在疫苗研发与推广上的积极进展与规划，流感作为常见且影响广泛的疾病，每年都会给公众健康带来较大威胁，有效流感疫苗的及时供应对于预防流感、降低感染率、减轻医疗系统负担意义重大。Moderna作为在疫苗领域具有重要影响力的企业，其流感疫苗若能在秋季顺利推向市场，有望为全球流感防控工作提供新的有力武器，为公众健康增添保障，也显示出该企业在应对公共卫生挑战方面的积极作为与责任担当，后续其疫苗研发进展及市场推广情况值得持续关注。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218205117a7073830&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260218205117a7073830&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4501","BK4532","BK4588","BK4139","MRNA","BK4534","BK4548","BK4585","BK4568","BK4551","BK4533"],"gpt_icon":0},{"id":"1147880710","title":"Moderna总裁：疫苗投资指引尚需更多稳定性确认","url":"https://stock-news.laohu8.com/highlight/detail?id=1147880710","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147880710?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:43","pubTimestamp":1771418593,"startTime":"0","endTime":"0","summary":"Moderna公司总裁近日表示，当前关于疫苗投资领域的指导建议仍存在波动，公司正等待相关指引展现出更明确的稳定性后再做决策。这一表态反映出生物科技企业在疫情后时代对投资风向的审慎评估态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4501","BK4533","BK4585","MRNA","BK4139","BK4548","BK4551","BK4532","BK4534","BK4588"],"gpt_icon":0},{"id":"1179667827","title":"异动解读 | FDA同意审查流感疫苗，Moderna盘前大涨5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179667827","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179667827?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:39","pubTimestamp":1771418340,"startTime":"0","endTime":"0","summary":"Moderna, Inc. (MRNA) 今日盘前股价大幅上涨5.28%，引起了市场的广泛关注。消息面上，美国食品和药物管理局（FDA）已同意对Moderna公司的季节性流感疫苗mRNA-1010进行审查。此前，FDA曾以试验设计存在缺陷为由拒绝了审查申请，而此次公司提交了修改后的方案，寻求全面批准该疫苗用于50至64岁人群，并加速批准用于65岁及以上人群，同时承诺在上市后进行额外的研究。这一监管进展被视为公司产品管线推进的重要一步。如果获得批准，该疫苗最早可能在2026/27年流感季节上市，为Moderna带来新的增长动力。欧洲、加拿大和澳大利亚的监管机构也在同步审查该候选疫苗。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8e8e39a7beb148acde163c9bfa12c7e1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","MRNA","MRNY"],"gpt_icon":0},{"id":"2612946448","title":"Moderna(MRNA.US)：美国食品药品监督管理局将启动对其在研季节性流感疫苗申报的审查。","url":"https://stock-news.laohu8.com/highlight/detail?id=2612946448","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612946448?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:04","pubTimestamp":1771416243,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8e8e39a7beb148acde163c9bfa12c7e1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","BK4548","BK4139","BK4501","MRNY","BK4585","MRNX","BK4588","MRNA","BK4551","BK4568","BK4533","BK4534"],"gpt_icon":0},{"id":"1142113696","title":"Moderna宣布美国FDA将启动对其季节性流感试验疫苗申报的审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1142113696","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142113696?lang=zh_cn&edition=full","pubTime":"2026-02-18 20:03","pubTimestamp":1771416200,"startTime":"0","endTime":"0","summary":"Moderna公司宣布，美国食品药品监督管理局（FDA）将启动对其季节性流感试验疫苗申报的审查工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8e8e39a7beb148acde163c9bfa12c7e1","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4139","BK4501","BK4585","BK4588","MRNA","BK4534","BK4532","BK4568","BK4551","BK4533"],"gpt_icon":0},{"id":"1116040878","title":"Coatue Management 投资组合变动：截至2025年12月31日，较同年9月30日季度对比","url":"https://stock-news.laohu8.com/highlight/detail?id=1116040878","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116040878?lang=zh_cn&edition=full","pubTime":"2026-02-18 06:30","pubTimestamp":1771367413,"startTime":"0","endTime":"0","summary":"知名投资机构Coatue Management披露了其截至2025年12月31日的投资组合变动情况。此次披露的数据主要与截至2025年9月30日的上一季度持仓进行比较，旨在展示该机构在特定时期内的资产配置调整与策略变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4533","BK4139","BK4568","BK4551","BK4501","BK4585","BK4588","MRNA","BK4534","BK4532"],"gpt_icon":0},{"id":"1167501095","title":"异动解读 | Moderna盘中大涨7.97%，四季度营收超预期及疫苗进展提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1167501095","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167501095?lang=zh_cn&edition=full","pubTime":"2026-02-13 22:48","pubTimestamp":1770994100,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘中股价大幅上涨7.97%，引起了市场的广泛关注。消息面上，Moderna公布的2025年第四季度财务业绩表现强劲，营收达到6.78亿美元，超出了市场分析师平均预期的6.261亿美元，这主要得益于其新冠疫苗在美国的销售好于预期。同时，公司重申了2026年营收同比增长10%的业绩指引，并预期美国市场与国际市场将各贡献约50%的营收，展现了均衡的全球化布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85bbc709c54701e4fb883d94fb5a7407","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","MRNX","MRNA"],"gpt_icon":0},{"id":"1130313502","title":"异动解读 | Moderna盘前大涨5.21%，四季度营收超预期及疫苗进展提振股价","url":"https://stock-news.laohu8.com/highlight/detail?id=1130313502","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130313502?lang=zh_cn&edition=full","pubTime":"2026-02-13 22:27","pubTimestamp":1770992873,"startTime":"0","endTime":"0","summary":"Moderna, Inc.  今日盘前股价大幅上涨5.21%，引起了市场的广泛关注。消息面上，Moderna公布的2025年第四季度财务业绩表现强劲，营收达到6.78亿美元，超出了市场分析师平均预期的6.261亿美元，这主要得益于其新冠疫苗在美国的销售好于预期。同时，公司重申了2026年营收同比增长10%的业绩指引，并预期美国市场与国际市场将各贡献约50%的营收，展现了均衡的全球化布局。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85bbc709c54701e4fb883d94fb5a7407","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MRNA"],"gpt_icon":0},{"id":"1136221151","title":"Moderna高管透露：公司期待年内获欧洲批准流感与新冠联合疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=1136221151","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136221151?lang=zh_cn&edition=full","pubTime":"2026-02-13 21:38","pubTimestamp":1770989892,"startTime":"0","endTime":"0","summary":"Moderna公司高管在电话会议中表示，公司正积极争取其流感与新冠联合疫苗在今年内获得欧洲监管机构的批准。\n这一表态凸显了Moderna在推进组合疫苗商业化进程中的关键步伐，若顺利获批，将有望为欧洲地区提供更高效的呼吸道疾病防护方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","BK4548","BK4534","BK4551","MRNX","BK4501","BK4532","BK4568","BK4588","BK4139","MRNA","BK4585","BK4533"],"gpt_icon":0},{"id":"1142377976","title":"Moderna四季度营收6.78亿美元好于预期，重申年度增速指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1142377976","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142377976?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:17","pubTimestamp":1770985052,"startTime":"0","endTime":"0","summary":"公司正在开发更新的产品。","market":"us","thumbnail":"https://static.tigerbbs.com/2f3840dad459cd6d96e214702ddd10d3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/2f3840dad459cd6d96e214702ddd10d3"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"85bbc709c54701e4fb883d94fb5a7407","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moderna四季度营收6.78亿美元好于预期，重申年度增速指引","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNX","MRNA","MRNY"],"gpt_icon":0},{"id":"1149918830","title":"Moderna预期2026年营收分布：美国与国际市场各占半壁江山","url":"https://stock-news.laohu8.com/highlight/detail?id=1149918830","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149918830?lang=zh_cn&edition=full","pubTime":"2026-02-13 20:03","pubTimestamp":1770984217,"startTime":"0","endTime":"0","summary":"Moderna公司最新预测显示，其2026年的全球营收结构将呈现均衡态势——预计美国本土市场与国际市场的贡献比例将分别达到约50%。这一战略展望凸显了该生物技术巨头在巩固北美业务的同时，正加速推进全球化布局的步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4139","MRNY","BK4568","MRNX","BK4548","BK4501","BK4585","BK4551","BK4534","MRNA","BK4532","BK4588"],"gpt_icon":0},{"id":"2611765489","title":"mRNA流感疫苗遭拒审后续：FDA指责Moderna无视“非常明确”的指导意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2611765489","media":"Minhua笔记","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611765489?lang=zh_cn&edition=full","pubTime":"2026-02-12 12:14","pubTimestamp":1770869655,"startTime":"0","endTime":"0","summary":"据《The Hill》报道，在生物技术公司谴责FDA拒绝审评其mRNA流感疫苗后，FDA予以反击。尽管如此，FDA当时也承认Moderna选择的对照“可以接受”。然而，在2月11日的新闻发布会上，FDA将RTF的责任完全归咎于Moderna。Moderna已向FDA申请召开A类会议，以了解RTF的具体原因，并寻求其实验性流感疫苗的下一步路径。据《The Hill》报道，一位未具名的FDA官员表示，如果Moderna“能够有所改进，甚至表现出一些谦逊”，他们或许可以重新提交相同的数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021214132697a5e677&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021214132697a5e677&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRNA","BK4548","BK4532","BK4501","BK4533","BK4551","BK4588","BK4534","BK4139","BK4585","CDC","BK4568"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.modernatx.com","stockEarnings":[{"period":"1week","weight":0.0404},{"period":"1month","weight":0.1377},{"period":"3month","weight":0.9904},{"period":"6month","weight":1.1465},{"period":"1year","weight":0.5399},{"period":"ytd","weight":0.7535}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Moderna, Inc.于2016年7月22日根据特拉华州法律注册成立。该公司是信使核糖核酸（信使核糖核酸）医学领域的领导者。通过在科学、技术和健康的交叉领域工作十多年，该公司以前所未有的速度和效率开发出药物，包括最早和最有效的新冠疫苗之一。该公司的mRNA平台已使传染病、免疫肿瘤学、罕见病和自身免疫性疾病的疗法和疫苗的开发成为可能。凭借独特的文化和由Moderna价值观和思维模式驱动的全球化团队，以负责任的方式改变人类健康的未来，该公司努力通过mRNA药物向人们传递尽可能大的影响。","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.112326},{"month":2,"riseRate":0.375,"avgChangeRate":0.010853},{"month":3,"riseRate":0.571429,"avgChangeRate":0.028598},{"month":4,"riseRate":0.714286,"avgChangeRate":0.123955},{"month":5,"riseRate":0.571429,"avgChangeRate":0.06219},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.025027},{"month":7,"riseRate":0.714286,"avgChangeRate":0.106584},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.089569},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.018964},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.032236},{"month":11,"riseRate":0.714286,"avgChangeRate":0.206001},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.033274}],"exchange":"NASDAQ","name":"Moderna, Inc.","nameEN":"Moderna, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Moderna, Inc.,MRNA,Moderna, Inc.股票,Moderna, Inc.股票老虎,Moderna, Inc.股票老虎国际,Moderna, Inc.行情,Moderna, Inc.股票行情,Moderna, Inc.股价,Moderna, Inc.股市,Moderna, Inc.股票价格,Moderna, Inc.股票交易,Moderna, Inc.股票购买,Moderna, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moderna, Inc.(MRNA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Moderna, Inc.(MRNA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}